Cureus | A Survival Analysis of Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy: A Single Center Experience | Article
Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis | SpringerLink
Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery | Anticancer Research
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma | NEJM
Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram
Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with
Overall survival curve. Median overall survival time was 8.2 months.... | Download Scientific Diagram
Frontiers | Treatment and survival analysis for 40-year SEER data on upper esophageal cancer
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma | Anticancer Research
VYXEOS® Efficacy - Phase 3 Trial Data vs 7+3 | VYXEOS® (daunorubicin and cytarabine)
survival - Time to event analysis - median (IQR) is <75% experience event - Cross Validated
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
Efficacy Data | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Kaplan–Meier survival curves. (A) Median overall survival was... | Download Scientific Diagram
Ambiguities in computing the median survival time. - FAQ 44 - GraphPad
Median overall survival according to changes in CA 19-9 | Open-i
Biology | Free Full-Text | Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
GraphPad Prism 10 Statistics Guide - Determining the median followup time
Metastasectomy and Targeted Therapy for Patients With Spinal Metastases of Renal Cell Carcinoma | International Journal of Spine Surgery
MARGENZA® Clinical Results
